Abstract:Objective To compare the clinical outcomes of prednisone therapy with prednisone plus cyclophosphamide therapy for IgA nephropathy (IgAN) combined with impaired renal function and nephrotic syndrome. Methods A total of 110 patients with renal biopsy-proven IgAN and nephrotic syndrome in Shanghai Ruijin Hospital from January 2004 to May 2010 were enrolled in this study. The patients were divided into steroid group (n=55, eGFR<70 mL·min-1·1.73 m-2 in 29 and eGFR>70 mL·min-1·1.73 m-2 in 26) and prednisone plus cyclophosphamide group (n=55, eGFR<70 mL·min-1·1.73 m-2 in 32 and eGFR>70 mL·min-1·1.73 m-2 in 23). Prednisone usage: 0.8-1 mg·kg-1·d-1 for 12 weeks, then decresed 10%-15% every 3 or 4 weeks until 10-15 mg/d for another 24 weeks. Cyclophosphamide usage: 0.5-0.75 g/m2, every 4 weeks for 6 times, then every 8 weeks for 3 times. ACEI or ARB could be used in hypertension patients. The mean follow-up period was 36 months. Serum albumin, 24-hour proteinuria and serum creatinine were monitored. Clinical baseline data and histological findings of two groups were compared. Results There were no significant differences in terms of age, gender, hypertension, hematuria, seralbumin, 24-hour proteinuria or serum creatinine between the two groups with various GFR before treatment (all P>0.05). Neither were the incidences of balloon sclerosis, mesangial hyperplasia, crescent formation, interstitial sclerosis, tubular atrophy or vascular lesions (all P>0.05). Serum albumin was significantly increased and 24-hour proteinuria was significantly decreased in all IgAN patients at 3 months after treatment (P<0.05). There was no significant difference of the level of serum creatinine before and after treatment in the patients with eGFR<70 mL·min-1·1.73 m-2 in the steroid group. However, in the cyclophosphamide group, the level of serum creatinine at the final follow-up was significantly higher than the baseline level (all P<0.05). The levels of serum creatinine before and after treatment were not significantly changed in patients with eGFR>70 mL·min-1·1.73 m-2 in either of the groups (all P>0.05). In steroid group, two patients had abnormal glucose tolerance, which was improved after steroid reduction; one patient suffered from liver damage and liver function became normal after treatment. In steroid plus cyclophosphamide group, one case had osteoporosis and 2 had abnormal glucose tolerance. No severe infections or other adverse reactions occurred in the patients of the two groups. Conclusion Both steroid therapy and cytotoxic medication can effectively reduce proteinuria in IgAN patients with impaired renal function. But there is no adequate evidence that cyclophosphamide is beneficial to the IgAN prognosis and can slow down renal function decline.

A comparison of the clinical efficacy of tonsillectomy with steroid pulse therapy and tonsillectomy therapy alone for patients with immunoglobulin A nephropathy: a retrospective observational study

Comparison of methods of steroid administration combined with tonsillectomy for IgA nephropathy patients

Histological Correlation between Tonsillar and Glomerular Lesions in Patients with IgA Nephropathy Justifying Tonsillectomy: A Retrospective Cohort Study

Immunosuppressive therapy for steroid-resistant nephrotic syndrome: a Bayesian network meta-analysis of randomized controlled studies

Long-term Efficacy of Tonsillectomy in Chinese Patients with IgA Nephropathy.

Efficacy and Safety of Glucocorticoids Therapy for IgA Nephropathy: a Meta-Analysis of Randomized Controlled Trials.

Comparison of steroid-pulse therapy and combined with mizoribine in IgA nephropathy: a randomized controlled trial

[Immunosuppression, tonsillectomy and remissions in high-risk IgA-nephropathy]

The role of tonsillectomy in IgA nephropathy

Effects of tonsillectomy in children with IgA nephropathy, purpura nephritis, or other chronic glomerulonephritides

A comparison of the effectiveness of cyclophosphamide, leflunomide, corticosteroids, or conservative management alone in patients with IgA nephropathy: a retrospective observational study

Comparison Of Glucocorticoids Alone And Combined With Cyclosporine A In Patients With Iga Nephropathy: A Prospective Randomized Controlled Trial

Acei/Arb Therapy for Iga Nephropathy: A Meta Analysis of Randomised Controlled Trials

Periodontal and ENT therapy in the treatment of pediatric Henoch-Schönlein purpura and IgA nephropathy

Efficacy and Safety of Immunosuppressive Monotherapy Agents for IgA Nephropathy: A Network Meta-Analysis

Combination Cyclophosphamide/Glucocorticoids Provide Better Tolerability and Outcomes versus Glucocorticoids Alone in Patients with Sjogren's Associated Chronic Interstitial Nephritis.

Pathologic tonsillar findings similar to IgA nephropathy and the role of tonsillectomy in a patient with nephrotic syndrome

Can tonsillectomy modify the innate and adaptive immunity pathways involved in IgA nephropathy?

Prednisone plus cyclophosphamide therapy for IgA nephropathy patients with impaired renal function and nephrotic syndrome

Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial

Effect of pulsed intravenous methylprednisolone with alternative low-dose prednisone on high-risk IgA nephropathy: a 18-month prospective clinical trial